Vanda Pharmaceuticals Inc. shares fell in the extended session Wednesday after the biotech drug developer said a study of its treatment for a type of eczema did not reach the stated goal. Vanda shares fell 6.7% to $15.86 after hours, following a brief halt in trading. The company said a mid-stage clinical study of its drug tradipitant showed that while the drug showed improvement in itching in patients with atopic dermatitis compared with a placebo, the results were not statistically significant.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News